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Abstract: Ovarian cancer has the highest fatality rate among the gynecologic cancers. The side effects,
high relapse rate, and drug resistance lead to low long-term survival rate (less than 40%) of patients
with advanced ovarian cancer. Theaflavin-3,3′-digallate (TF3), a black tea polyphenol, showed less
cytotoxicity to normal ovarian cells than ovarian cancer cells. We aimed to investigate whether TF3
could potentiate the inhibitory effect of cisplatin against human ovarian cancer cell lines. In the
present study, combined treatment with TF3 and cisplatin showed a synergistic cytotoxicity against
A2780/CP70 and OVCAR3 cells. Treatment with TF3 could increase the intracellular accumulation of
platinum (Pt) and DNA-Pt adducts and enhanced DNA damage induced by cisplatin in both cells.
Treatment with TF3 decreased the glutathione (GSH) levels and upregulated the protein levels of
the copper transporter 1 (CTR1) in both cells, which led to the enhanced sensitivity of both ovarian
cancer cells to cisplatin. The results imply that TF3 might be used as an adjuvant to potentiate the
inhibitory effect of cisplatin against advanced ovarian cancer.
Keywords: theaflavin-3,3′-digallate; cisplatin; ovarian cancer; copper transporter 1; glutathione
1. Introduction
Ovarian cancer is the tenth most common cancer and the fifth leading cause of cancer death
among women in the United States [1]. Ovarian cancer causes a higher death rate than any other
gynecologic cancer, leading to approximately 5% of cancer deaths among women. The conventional
treatment for advanced ovarian cancer is surgical resection of the tumor mass followed by platinum
based-chemotherapy [2]. Although most patients with advanced ovarian cancer respond well to the
first-line conventional treatment, 70% of the patients relapse within 18 months of the treatment [3].
Moreover, the used chemotherapeutic agents often become ineffective to relapsing patients. The high
relapse rate and drug resistance lead to low long-term survival rate (less than 40%) of patients with
advanced ovarian cancer [4].
Cisplatin is the first platinum-based drug approved for ovarian cancer and one of the most active
chemotherapy agents for the treatment of ovarian cancer. In cells, DNA is the primary target of
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cisplatin. The mechanism of its antitumor action is related to crosslinking the purine in the DNA
chain forming intra-strand and inter-strand cross-linking [5]. Multiple mechanisms are involved in
the antitumor effect of cisplatin, of which the most known mode of action is to activate DNA damage
response and induce mitochondrial apoptosis triggered by generating DNA lesions [6]. Cisplatin
resistance attenuates its antitumor effect and limits its clinical employment. Mechanisms of cisplatin
resistance are complex, which is always accompanied by reduced intracellular accumulation, increased
sequestration, increased DNA lesion repair, and alterations in apoptotic signaling pathways [7].
Several studies demonstrated that copper transporter 1 (CTR1) is a major transmembrane protein
involving the uptake of cisplatin. Enhanced expression of CTR1 sensitized ovarian cancer cells to
cisplatin by increasing cisplatin uptake [8]. CTR1 defect embryonic fibroblasts were more resistant to
cisplatin than the wild-type counterparts [9]. Pre-treatment with copper was able to protect cells from
cisplatin cytotoxicity, whereas copper chelator led to increased cisplatin uptake and enhanced cisplatin
cytotoxicity [10,11]. Multidrug resistance protein 2 (MRP2), copper-transporting P-type ATPase
(ATP7A and ATP7B), and glutathione (GSH) are the major proteins mediating cisplatin resistance
by increasing cisplatin efflux. Overexpression of MRP2 led to cisplatin resistance in melanoma cells
by decreasing the formation of cisplatin-DNA adducts [12]. Increased expression of ATP7A led to
cisplatin resistance in ovarian cancer cells [13]. Moreover, clinical study indicated that ATP7B was a
cisplatin-resistant marker in ovarian cancer [14]. Cisplatin bound stably to GSH in cytoplasm before it
was transferred into the nucleus and mitochondria, which limited the amount of cisplatin reacting
with DNA [15]. In addition, the GSH-cisplatin complexes were readily exported by MRP2 [16]. Thus,
cisplatin transporters and GSH play an important role in cisplatin resistance. Targeting cisplatin
transporters and GSH might be an effective intervention to overcome cisplatin resistance.
TF3 is a polyphenolic compound extracted from black tea and is formed via the co-oxidation of
(−)-epigallocatechin gallate (EGCG) and (−)-epicatechin gallate during black tea production [17]. TF3
has shown potent antioxidant [18], anti-inflammatory [19], and anticancer properties [20–22]. We have
previously reported that TF3 inhibited human ovarian cancer cells by inducing apoptosis and cell cycle
arrest [23] and by suppressing angiogenesis [24]. In the present study, we investigated whether TF3
could potentiate the inhibitory effect of cisplatin against human ovarian cancer cell lines.
2. Results
2.1. The Synergistic Inhibitory Effect of TF3 and Cisplatin Against Ovarian Cancer Cells
To determine the synergistic inhibitory effect of TF3 and cisplatin against ovarian cancer
A2780/CP70 and OVCAR3 cells, we evaluated the combination index (CI) of TF3 and cisplatin
at a constant ratio of 1:1 (µM:µM). The viability of both cells treated with TF3, cisplatin, and their
combination was determined using the MTS assay. As shown in Figure 1A,B, TF3, cisplatin, and the
combination treatment decreased the viability of both cells in a dose-dependent manner. CI values
were calculated using CalcuSyn software. As shown in Figure 1C, the CI values of combination
treatment at the designated concentration were less than 1.0, which indicated that the inhibitory effect
of TF3 and cisplatin combination treatment against ovarian cancer cells was synergistic.
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Figure 1. The synergistic inhibitory effect of TF3 and cisplatin against ovarian cancer A2780/CP70 
and OVCAR3 cells. (A) The cell viability of A2780/CP70 cells treated with TF3, cisplatin, or their 
combination at a ratio of 1:1 (μM:μM) at the designated concentrations; (B) the cell viability of 
OVCAR3 cells treated with TF3, cisplatin, or their combination at a ratio of 1:1 (μM:μM) at the 
designated concentrations; (C) the CI values of TF3 and cisplatin combination treatment against both 
cells at a constant ratio of 1:1 (μM:μM) at the designated concentrations were less than 1.0, indicating 
synergism. Results are expressed as mean ± SD from three independent experiments. 
2.2. TF3 Increases Intracellular Accumulation of Total Pt and DNA-Pt Adducts 
To investigate whether the synergistic inhibitory effect of TF3 and cisplatin against ovarian 
cancer A2780/CP70 and OVCAR3 cells resulted from changes in intracellular Pt accumulation, the 
total Pt and DNA-Pt adducts in cells were measured by ICP-MS. As shown in Figure 2, treatment 
with TF3 significantly increased the accumulation of total Pt and DNA-Pt adducts in A2780/CP70 
and OVCAR3 cells (p < 0.05). The total Pt accumulated in A2780/CP70 cells treated with 7.5 μM 
cisplatin for 6 h was 11.90 ± 1.12 ng Pt/mg protein, which was significantly lower than that (15.05 ± 
1.02 ng Pt/mg protein) in cells treated with 7.5 μM TF3 and cisplatin. The Pt-DNA adducts 
accumulated in A2780/CP70 cells treated with 7.5 μM cisplatin for 6 h was 2.14 ± 0.19 ng Pt/μg DNA, 
which was significant lower than that (3.01 ± 0.23 ng Pt/μg DNA) in cells treated with 7.5 μM TF3 
and cisplatin. The total Pt accumulated in OVCAR3 cells treated with 7.5 μM cisplatin for 6 h was 
14.32 ± 1.36 ng Pt/mg protein, which was significant lower than that (17.45 ± 0.82 ng Pt/mg protein) 
in cells treated with 7.5 μM TF3 and cisplatin. The Pt-DNA adducts accumulated in OVCAR3 cells 
treated with 7.5 μM cisplatin for 6 h was 2.35 ± 0.22 ng Pt/μg DNA, which was significantly lower 
than that (3.22 ± 0.32 ng Pt/μg DNA) in cells treated with 7.5 μM TF3 and cisplatin. Therefore, 
treatment with TF3 could increase the accumulation of Pt in both cells and nuclei, which led to the 
synergistic effect of TF3 and cisplatin against ovarian cancer cells. 
Figure 1. The synergistic inhibitory effect of TF3 and cisplatin against ovarian cancer A2780/CP70
and OVCAR3 cells. (A) The cell viability of A2780/CP70 cells treated with TF3, cisplatin, or their
combination at a ratio of 1:1 (µM:µM) at the designated concentrations; (B) the cell viability of OVCAR3
cells treated with TF3, cisplatin, or their combination at a ratio of 1:1 (µM:µM) at the designated
concentrations; (C) the CI values of TF3 and cisplatin combination treatment against both cells at a
constant ratio of 1:1 (µM:µM) at the designated concentrations were less than 1.0, indicating synergism.
Results are expressed as mean ± SD from three independent experiments.
2.2. TF3 Increases Intracellular Accumulation of Total Pt and DNA-Pt Adducts
To investigate whether the synergistic inhibitory effect of TF3 and cisplatin against ovarian cancer
A2780/CP70 and OVCAR3 cells resulted from changes in intracellular Pt accumulation, the total Pt
and DNA-Pt adducts in cells were measured by ICP-MS. As shown in Figure 2, treatment with TF3
significantly increased the accumulation of total Pt and DNA-Pt adducts in A2780/CP70 and OVCAR3
cells (p < 0.05). The total Pt accumulated in A2780/CP70 cells treated with 7.5 µM cisplatin for 6 h was
11.90± 1.12 ng Pt/mg protein, which was significantly lower than that (15.05± 1.02 ng Pt/mg protein)
in cells treated with 7.5 µM TF3 and cisplatin. The Pt-DNA adducts accumulated in A2780/CP70 cells
treated with 7.5 µM cisplatin for 6 h was 2.14 ± 0.19 ng Pt/µg DNA, which was significant lower
than that (3.01 ± 0.23 ng Pt/µg DNA) in cells treated with 7.5 µM TF3 and cisplatin. The total Pt
accumulated in OVCAR3 cells treated with 7.5 µM cisplatin for 6 h was 14.32 ± 1.36 ng Pt/mg protein,
which was significant lower than that (17.45 ± 0.82 ng Pt/mg protein) in cells treated with 7.5 µM TF3
and cisplatin. The Pt-DNA adducts accumulated in OVCAR3 cells treated with 7.5 µM cisplatin for
6 h was 2.35 ± 0.22 ng Pt/µg DNA, which was significantly lower than that (3.22 ± 0.32 ng Pt/µg
DNA) in cells treated with 7.5 µM TF3 and cisplatin. Therefore, treatment with TF3 could increase
the accumulation of Pt in both cells and nuclei, which led to the synergistic effect of TF3 and cisplatin
against ovarian cancer cells.
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Figure 2. Effects of TF3 on the accumulation of Pt and DNA-Pt adducts in A2780/CP70 and OVCAR3 
cells. Cells were treated with 7.5 μM cisplatin or 7.5 μM combined TF3 and cisplatin for 6 h followed 
by the ICP-MC assay. (A) Effects of TF3 on the accumulation of Pt and DNA-Pt adducts in 
A2780/CP70 cells; (B) effects of TF3 on the accumulation of Pt and DNA-Pt adducts in OVCAR3 cells. 
Data represent means ± SD of three independent experiments. Significant differences among 
different treatments are marked with * (p < 0.05). 
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Cisplatin is known to exert antitumor effect mainly by inducing DNA damage. DNA damage 
levels in ovarian cancer cells were determined by Western blot analysis and enzyme-linked 
immunosorbent assay (ELISA) assay. Ataxia telangiectasia mutated kinase (ATM), a 
serine/threonine kinase, is a key sensor and transducer of DNA damage signals. ATM is 
phosphorylated on Ser1981 induced by DNA damage and phosphorylates series of downstream 
signaling molecules. The p53 protein phosphorylated by ATM at Ser15 in response to DNA damage. 
As shown in Figure 3A, treatment with 7.5 μM TF3 had no significant effect on the protein levels of 
p-ATM (Ser1981) and p-p53 (Ser15) (p > 0.05). Treatment with 7.5 μM cisplatin significantly 
upregulated the protein levels of p-ATM (Ser1981) and p-p53 (ser15) (p < 0.05). The protein levels of 
p-ATM (Ser1981) and p-p53 (Ser15) were significantly higher in both cells subjected to combination 
treatment compared to the untreated control cells and cells treated with either agent alone (p < 0.05). 
The phosphorylation of Histone H2A.X at Ser139 is a marker of DNA damage, which was detected 
using ELISA assay. As shown in Figure 3B, treatment with 7.5 μM TF3 had no significant effect on 
the protein level of p-Histon H2A.X (Ser139) (p > 0.05). Treatment with 7.5 μM cisplatin significantly 
upregulated the protein level of p-Histon H2A.X (Ser139) (p < 0.05). The protein level of p-Histon 
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ovarian cancer cells. 
Figure 2. Effects of TF3 on the accumulation of Pt and DNA-Pt adducts in A2780/CP70 and OVCAR3
cells. Cells were treated with 7.5 µM cisplatin or 7.5 µM combined TF3 and cisplatin for 6 h followed by
the ICP-MC assay. (A) Effects of TF3 on the accumulation of Pt and DNA-Pt adducts in A2780/CP70
cells; (B) effects of TF3 on the accumulation of Pt and DNA-Pt adducts in OVCAR3 cells. Data represent
means ± SD of three independent experiments. Significant differences among different treatments are
marked with * (p < 0.05).
2.3. TF3 Enhanced DNA Damage Induced by Cisplatin in Ovarian Cancer Cells
Cisplatin is known to exert antitumor effect mainly by inducing DNA damage. DNA damage
levels in ovarian cancer cells were determined by Western blot analysis and enzyme-linked
immunosorbent assay (ELISA) assay. Ataxia telangiectasia mutated kinase (ATM), a serine/threonine
kinase, is a key sensor and transducer of DNA damage signals. ATM is phosphorylated on Ser1981
induced by DNA damage and phosphorylates series of downstream signaling molecules. The p53
protein phosphorylated by ATM at Ser15 in response to DNA damage. As shown in Figure 3A,
treatment with 7.5 µM TF3 had no significant effect on the protein levels of p-ATM (Ser1981) and
p-p53 (Ser15) (p > 0.05). Treatment with 7.5 µM cisplatin significantly upregulated the protein levels of
p-ATM (Ser1981) and p-p53 (ser15) (p < 0.05). The protein levels of p-ATM (Ser1981) and p-p53 (Ser15)
were significantly higher in both cells subjected to combination treatment compared to the untreated
control cells and cells treated with either agent alone (p < 0.05). The phosphorylation of Histone H2A.X
at Ser139 is a marker of DNA damage, which was detected using ELISA assay. As shown in Figure 3B,
treatment with 7.5 µM TF3 had no significant effect on the protein level of p-Histon H2A.X (Ser139)
(p > 0.05). Treatment with 7.5 µM cisplatin significantly upregulated the protein level of p-Histon
H2A.X (Ser139) (p < 0.05). The protein level of p-Histon H2A.X (Ser139) were significantly higher in
both cells subjected to combination treatment than in untreated control cells and cells treated with
either agent alone (p < 0.05). The results of Western blot analysis and ELISA assay indicated that TF3
can enhance DNA damage induced by cisplatin in ovarian cancer cells.
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against ovarian cancer A2780/CP70 and OVCAR3 cells, the effect of TF3 on GSH levels and the effect 
of GSH on cell sensitivity to cisplatin were investigated. As shown in Figure 4A, treatment with TF3 
decreased the GSH levels in both cells in a dose-dependent manner. Treatment with 7.5 μM cisplatin 
significantly increased the GSH levels in both cells (p < 0.01). GSH level in cells treated with 
combined 7.5 μM TF3 and cisplatin was significant lower than that in cells treated with 7.5 μM 
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Buthionine sulphoximine (BSO), an irreversible inhibitor of γ-glutamylcysteine synthetase, was 
used to decreased GSH levels in cells. As shown in Figure 4B, treatment with BSO decreased the 
Figure 3. Treatment with 7.5 µM TF3 enhanced DNA damage induced by 7.5 µM cisplatin in ovarian
cancer A2780/CP70 and OVCAR3 cells. (A) The effect of TF3, cisplatin and combination treatment
of the protein levels of p-ATM and p-p53 in ovarian cancer cells were determined by Western blot
analysis; (B) the effect of TF3, cisplatin and combination treatment of the protein level of p-Histon
H2A.X in ovarian cancer cells was determined by ELISA assay. Results are expressed as mean ± SD
from three independent experiments. Significant differences among different treatments are marked
with different letters (p < 0.05).
2.4. TF3 Synergistically Inhibited Ovarian Cancer Cells with Cisplatin by Reducing glutathione (GSH) Levels
in the Cells
To verify whether GSH was involved in the synergistic inhibitory effect of TF3 and cisplatin
against ovarian cancer A2780/CP70 and OVCAR3 cells, the effect of TF3 on GSH levels and the effect
of GSH on cell sensitivity to cisplatin were investigated. As shown in Figure 4A, treatment with TF3
decreased the GSH levels in both cells in a dose-dependent manner. Treatment with 7.5 µM cisplatin
significantly increased the GSH levels in both cells (p < 0.01). GSH level in cells treated with combined
7.5 µM TF3 and cisplatin was significant lower than that in cells treated with 7.5 µM cisplatin (p < 0.01).
Buthionine sulphoximine (BSO), an irreversible inhibitor of γ-glutamylcysteine synthetas , was
used to decreased GSH levels in cells. As shown in Figure 4B, treatment with BSO decreased the GSH
levels in both cells in a dose-dependent manner. The reduced GSH levels induced by treatment with
2.0 µM BSO had no significant difference with that induced by treatment with 7.5 µM TF3, so that
BSO at the concentration of 2.0 µM was used to investigate the effect of the reduced GSH levels on
Int. J. Mol. Sci. 2018, 19, 117 6 of 12
cell sensitivity to cisplatin. As shown in Figure 4C,D, Pretreatment with BSO significant increased the
percentage of total apoptotic cells (p < 0.01 or 0.05). As shown in Figure 4E, BSO significantly enhanced
the inhibitory effect of cisplatin against cell viability (p < 0.01 or 0.05). The results of flow cytometry
analysis and cell viability assay indicated that the reduced GSH levels could enhance the sensitivity of
both cells to cisplatin.
Taken together, treatment with TF3 potentiated the inhibitory effect of cisplatin against ovarian
cancer A2780/CP70 and OVCAR3 cells by reducing GSH levels in both cells.
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Figure 4. Treatment with TF3 potentiated inhibitory effect of cisplatin against ovarian cancer
A2780/CP70 and OVCAR3 cells via reducing GSH levels. (A) The effect of TF3, cisplatin, or combination
treatment on the GSH levels in ovarian cancer cells. The statistical difference analysis was performed
between the groups at both ends of the broken lines with arrows; (B) treatment with BSO decreased the
GSH levels in ovarian cancer cells in a dose-dependent manner.; (C) pretreatment with 2.0 µM BSO
enhanced the pro-apoptotic effect of 7.5 µM cisplatin on ovarian cancer cells; (D) the changes of total
apoptotic cell population induced by 7.5 µM cisplatin in control cells and cells pretreated with 2.0 µM
BSO were expressed as quantification histograms with error bars; (E) pretreatment with 2.0 µM BSO
enhanced the inhibitory effect of 7.5 µM cisplatin on the viability of ovarian cancer cells. Results are
expressed as mean ± SD from three independent experiments. Significant differences among different
treatments are marked with * (p < 0.05) and ** (p < 0.01).
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2.5. TF3 Upregulated the Protein Expression of CTR1 in Ovarian Cancer Cells
Since cisplatin transporters can mediate the resistance of ovarian cancer cells to cisplatin, the
protein levels of MRP2, ATP7A, ATP7B, and CTR1 in ovarian cancer A2780/CP70 and OVCAR3 cells
were evaluated by Western blot analysis. As shown in Figure 5A, treatment with TF3 had no significant
effect on the protein levels of MRP2, ATP7A, and ATP7B (p > 0.05) and upregulated the protein level
of CTR1 in a dose-dependent manner. We further evaluated the effect of TF3 on the CTR1 protein
level in cells treated with cisplatin. As shown in Figure 5B, treatment with 7.5 µM TF3 significantly
upregulated the CTR1 protein level in cells treated with 7.5 µM cisplatin (p < 0.05). To further verify
the correlation between CTR1 and cisplatin sensitivity, CTR1 in both cells were knocked down by
transfection with CTR1 siRNA (Figure 5C) and then subjected to cell viability assay. As shown in
Figure 5D, transfection with CTR1 siRNA significantly attenuated the inhibitory effect of 7.5 µM
cisplatin on the cell viability of both cells (p < 0.01), indicating that the protein level of CTR1 mediated
cisplatin resistance of both cells.
Taken together, treatment with TF3 could enhance the sensitivity of ovarian cancer A2780/CP70
and OVCAR3 cells to cisplatin by upregulating CTR1 protein expression in the cells.
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Figure 5. Treatment with TF3 potentiated inhibitory effect of cisplatin against ovarian cancer
A2780/CP70 and OVCAR3 cells via upregulating CTR1 protein expression. (A) The effect of TF3
at the designated concentrations on the protein levels of MRP2, ATP7A, ATP7B and CTR1 in ovarian
cance cells; (B) treatment with 7.5 µM TF3 upregulated CTR1 protein levels in ova ian cancer cells
pretreated with 7.5 µM cisplatin; (C) transfection with CTR1 siRNA d cre sed CTR1 protein levels
in ovarian cancer cells; (D) transfection with CTR1 siRNA enhanced the resistance of ovaria cancer
cells to 7.5 µM cisplatin. Results are expressed as mean ± SD from three independent experiments.
Significant differences among different treatments are marked with different letters (p < 0.05), * (p < 0.05)
and ** (p < 0.01).
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3. Discussion
Cisplatin is one of the widely used chemotherapeutic drugs for cancer therapy. The resistance of
ovarian cancer to cisplatin is a pivotal cause leading to its high lethal rate. The resistance to cisplatin is
associated with reduced intracellular cisplatin accumulation, resulting from impaired intake, enhanced
efflux, and increased sequestration of cisplatin. Thus, increasing intracellular cisplatin accumulation
is a good way to overcome drug resistance. The combination therapy based on chemotherapeutic
drugs and natural compounds has been reported to increase intracellular cisplatin accumulation by
modulating cisplatin transport. EGCG enhances cisplatin sensitivity by regulating expression of CTR1
in ovarian cancer cells [25] and lung cancer cells [26]. The combination of glycyrrhizin and lamivudine
attenuates the resistance of hepatocellular cancer cells to cisplatin through the inhibition of MRPs [27].
A reduction of intracellular GSH levels decreases the sequestration of cisplatin [28]. In the present
study, we found that TF3 potentiates the inhibitory effect of cisplatin against ovarian cancer cells by
modulating cisplatin transport and GSH.
In the present study, an MTS assay was first used to evaluate the synergistic inhibitory effect of
TF3 and cisplatin against ovarian cancer A2780/CP70 and OVCAR3 cells. The combination treatment
CI values were less than 1.0, indicating that the inhibitory effect was synergistic. Since the CI values
of combined TF3 and cisplatin (7.5 µM:7.5 µM) were the lowest, TF3 and cisplatin at a ratio of
7.5 µM:7.5 µM was used for further study. Cisplatin exerted an antitumor effect mainly by inducing
DNA damage. Furthermore, we determined the content of Pt and DNA-Pt adducts and DNA damage
in ovarian cancer A2780/CP70 and OVCAR3 cells. Treatment with 7.5 µM TF3 significantly increased
the intracellular accumulation of Pt and DNA-Pt adducts in both cells (p < 0.05). Treatment with
TF3 enhanced DNA damage induced by cisplatin in both cells. The synergistic inhibitory effect
of TF3 and cisplatin against ovarian cancer cells was involved in increased intracellular cisplatin
accumulation. It has been reported that EGCG increases intracellular cisplatin accumulation by
regulating the expression of CTR1 in ovarian cancer cells [25]. TF3 derives from EGCG. The same
function groups of TF3 and EGCG might exert a synergistic inhibitory effect by increasing intracellular
cisplatin accumulation in ovarian cancer cells.
GSH is a thiol-containing tripeptide consisting of glutamate, cysteine, and glycine. GSH is believed
to be the major cellular target of cisplatin, which inactivates cisplatin by binding to it irreversibly.
Cisplatin-resistant ovarian cancer cells often show elevated levels of cellular GSH [29–31]. In the
present study, we found that treatment with TF3 decreased GSH levels and attenuated the elevation
of GSH levels induced by cisplatin in ovarian cancer A2780/CP70 and OVCAR3 cells. Depletion of
GSH enhanced the cytotoxicity of cisplatin against both cells. Taken together, the combined treatment
with TF3 sensitized ovarian cancer cells to cisplatin by decreasing the cellular GSH levels. GSH is
an important antioxidant that protects important cellular components from reactive oxygen species.
It has been reported that TF3 inhibits human squamous carcinoma HSC-2 cells by inducing oxidative
stress and reducing GSH levels [32]. Theaflavins induce oxidative stress and deplete GSH in human
squamous carcinoma HSC-2 and CAL27 cells [33,34]. TF3 might decrease the GSH levels in ovarian
cancer cells by inducing oxidative stress and further sensitize ovarian cancer cells to cisplatin.
Cisplatin transporters are important mediators of cellular uptake and efflux modulating the
intracellular cisplatin accumulation, which determines the cytotoxicity of cisplatin [35]. In the present
study, cisplatin transporters, including MRP2, ATP7A, ATP7B, and CTR1, were determined by Western
blot analysis. Treatment with TF3 upregulated the protein levels of CTR1 in ovarian cancer A2780/CP70
and OVCAR3 cells, but had no significant effect on the protein levels of MRP2, ATP7A and ATP7B
(p > 0.05). Treatment with TF3 also upregulated the protein levels of CTR1 in both cells treated with
cisplatin. Furthermore, knockdown of CTR1 with siRNA significantly attenuated the inhibitory effect
of cisplatin on the viability of both cells. CTR1 is a major transmembrane protein involving the uptake
of cisplatin [36]. Enhanced expression of CTR1 sensitizes cancer cells to cisplatin by increasing cisplatin
uptake [37]. The high expression level of CTR1 was found to be a prognostic factor for the improved
survival of patients with advanced ovarian cancer [38]. Upregulated expression of CTR1 induced by
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TF3 enhances the sensitivity of ovarian cancer cells to cisplatin, and the upregulation of CTR1 induced
by EGCG mediates cisplatin sensitivity in ovarian cancer cells [25].
4. Materials and Methods
4.1. Cell Culture and Reagents
Human ovarian cancer cell lines A2780/CP70 and OVCAR3 were obtained from Bing-Hua Jiang
at West Virginia University. The cells were cultured in RPMI-1640 medium (Sigma, St Louis, MO, USA)
supplemented with 10% fetal bovine serum (Invitrogen, Rockford, IL, USA), 1% penicillin (100 U/mL),
streptomycin (10 µg/mL), and amphotericin-B (250 µg/mL) (Sigma, St Louis, MO, USA) at 37 ◦C
with 5% CO2 in a humidified incubator. TF3 monomers were isolated and purified using a previously
established method [39]. Cisplatin was purchased from Sigma-Aldrich (Sigma, St Louis, MO, USA).
TF3 and cisplatin were prepared in distilled water and stored at −20 ◦C. CTR1 siRNA and control
siRNA were purchased from Santa Cruz Biotechnology (Danvers, MA, USA).
4.2. Cell Viability Assay
Cells were seeded in 96-well plates at 2 × 104 cells per well and incubated for 12 h. The medium
was replaced by treatment medium. After 24 h of treatment, CellTiter 96® Aqueous One Solution
Cell Proliferation Assay kit (Promega, St Louis, MO, USA) was used to determine cell viability. Cell
viability was normalized by that of control cells for analysis.
4.3. Measurement of Intracellular Pt Accumulation
Cells were seeded in 6 cm dishes at 1 × 106 cells per dish and incubated for 12 h. The medium
was replaced by treatment medium. After 6 h of treatment, the cells were washed with phosphate
buffered solution (PBS) to remove free cisplatin and harvested by trypsin. The protein concentrations
were determined with BCA Protein assay kit (Pierce, St Louis, MO, USA). Total Pt content accumulated
in cells was determined by Element 2 inductively coupled plasma mass spectrometry (ICP-MS)
(Thermo Fisher, Waltham, MA, USA). To measure the content of Pt binding to DNA, DNA was
extracted using PureLink™ Genomic DNA Mini Kit (Invitrogen, Rockford, IL, USA), according to
the manufacturer’s protocol. The quantitation of DNA was measured using a Qubit Fluorometer
(Invitrogen, Rockford, IL, USA). The samples were then digested in 5% nitric acid and measured
by ICP-MS.
4.4. GSH Assay
Cells were seeded in 96-well plates at 2 × 104 cells per well and incubated for 12 h. The medium
was replaced by treatment medium. After 24 h of treatment, GSH levels in cells were detected using
a GSH-Glo™ Glutathione Assay kit (Promega, St Louis, MO, USA) according to the manufacturer’s
instructions. GSH levels were normalized by total protein levels and were expressed as percentage of
the untreated control. The total protein levels were measured with a BCA assay kit.
4.5. Flow Cytometric Analysis of Apoptotic Cells
Cells were seeded in 6 cm dishes at 1× 106 cells per dish and incubated for 12 h. The medium was
replaced by treatment medium. After 24 h of treatment, the cells were washed with PBS and harvested
by trypsin. Cells were suspended in binding buffer and then stained with Alexa Fluor 488Annexin V
and propidium iodide (PI) for 15 min. The cells were stained and then analyzed via flow cytometry
(FACSCalibur system, BD Biosciences, Franklin Lakes, NJ, USA).
4.6. Cell-Based Phosphorylation ELISA Assay
Cells were seeded in 96-well plates at 2 × 104 cells per well and incubated for 12 h. The medium
was replaced by treatment medium. After 24 h of treatment, the treatment medium was removed.
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The amounts of phosphorylated Histone H2A.X were detected using a Phospho-H2A.X Cell-Based
Phosphorylation ELISA Kit (LSBio, Seattle, WA, USA) according to the manufacturer’s instructions.
The amounts of phosphorylated Histone H2A.X were normalized by total protein levels and were
expressed as percentage of the untreated control. The total protein levels were measured with a BCA
assay kit.
4.7. Western Blotting
Cells were seeded in 6 cm dishes at 1 × 106 cells per dish and incubated for 12 h. The medium
was replaced by treatment medium. After 24 h of treatment, cells were lysed using M-PER Mammalian
Protein Extraction Reagent (Pierce, St Louis, MO, USA) supplemented with Halt™ Protease and
Phosphatase Inhibitor Single-Use Cocktail (Life Technologies, Grand Island, NY, USA). The protein
levels were determined using BCA Protein assay kit. After boiling for 6 min in loading buffer
(Bio-Rad, Hercules, CA, USA), equal amounts of protein were subjected to sodium dodecyl sulfate
polyacrylamide gel electrophoresis. The separated proteins were transferred onto a nitrocellulose
blotting membrane. The membrane was blocked with 5% nonfat dried milk in Tris Buffered Saline
(Bio-Rad, Hercules, CA, USA) containing 0.1% Tween-20 (TBST) at room temperature for 1 h and
subsequently incubated with specific primary antibodies overnight at 4 ◦C. The membrane was washed
three times (10 min each) with TBST and then incubated with an appropriate secondary antibody
conjugated with horseradish peroxide for 1 h at room temperature. After three 10 min washes with
TBST, antigen–antibody complex in each blot was visualized with Super Signal West Dura Extended
Duration Substrate (Life Technologies, Grand Island, NY, USA) and ChemiDoc™ MP System (Bio-Rad,
Hercules, CA, USA). Protein bands were quantitated with NIH ImageJ software and normalized by
GAPDH bands for analysis.
4.8. Transfection with Small Interfering RNA (siRNA)
Cells were seeded in 6 cm dishes at 5 × 105 cells per dish and incubated for 12 h. Then, CTR1
siRNA or control siRNA were transfected into the cells using Lipofectamine 2000 transfection reagent
(Invitrogen, Rockford, IL, USA) according to the manufacturer’s instruction. Then the transfected cells
were used for cell viability assay and Western blotting analysis.
4.9. Statistical Analysis
The data were expressed as mean ± standard deviations. A least significant difference test
was used to analyze multiple comparisons. A Student’s t-test was used to analyze the statistical
difference between two groups. Statistically significant difference and highly significant difference
were presented as p < 0.05 and p < 0.01, respectively.
5. Conclusions
In conclusion, our study revealed that TF3 potentiated the inhibitory effect of cisplatin against
ovarian cancer A2780/CP70 and OVCAR3 cells by increasing the accumulation of intracellular Pt and
DNA-Pt adducts. Treatment with TF3 downregulated cellular GSH levels and upregulated the protein
expression of CTR1, resulting in elevated intracellular cisplatin accumulation. TF3 was a potential
agent to reduce the side effect of cisplatin and overcome the cisplatin resistance of ovarian cancer cells.
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